Literature DB >> 23701416

Genome engineering at the dawn of the golden age.

David J Segal1, Joshua F Meckler.   

Abstract

Genome engineering--the ability to precisely alter the DNA information in living cells--is beginning to transform human genetics and genomics. Advances in tools and methods have enabled genetic modifications ranging from the "scarless" correction of a single base pair to the deletion of entire chromosomes. Targetable nucleases are leading the advances in this field, providing the tools to modify any gene in seemingly any organism with high efficiency. Targeted gene alterations have now been reported in more than 30 diverse species, ending the reign of mice as the exclusive model of mammalian genetics, and targetable nucleases have been used to modify more than 150 human genes and loci. A nuclease has also already entered clinical trials, signaling the beginning of genome engineering as therapy. The recent dramatic increase in the number of investigators using these techniques signifies a transition away from methods development toward a new age of exciting applications.

Entities:  

Mesh:

Year:  2013        PMID: 23701416     DOI: 10.1146/annurev-genom-091212-153435

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  48 in total

Review 1.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

2.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

Review 3.  Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

Authors:  Samantha A Nicholson; Buhle Moyo; Patrick B Arbuthnot
Journal:  World J Hepatol       Date:  2015-04-28

4.  Biallelic genome modification in F(0) Xenopus tropicalis embryos using the CRISPR/Cas system.

Authors:  Ira L Blitz; Jacob Biesinger; Xiaohui Xie; Ken W Y Cho
Journal:  Genesis       Date:  2013-11-21       Impact factor: 2.487

5.  Dual-reporter surrogate systems for efficient enrichment of genetically modified cells.

Authors:  Chonghua Ren; Kun Xu; Zhongtian Liu; Juncen Shen; Furong Han; Zhilong Chen; Zhiying Zhang
Journal:  Cell Mol Life Sci       Date:  2015-03-01       Impact factor: 9.261

Review 6.  CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.

Authors:  Muhammad R Javed; Maria Sadaf; Temoor Ahmed; Amna Jamil; Marium Nawaz; Hira Abbas; Anam Ijaz
Journal:  Curr Microbiol       Date:  2018-08-04       Impact factor: 2.188

Review 7.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

Review 8.  Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities.

Authors:  Pranav Mathur; Jun Yang
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 9.  Nanomedicine: tiny particles and machines give huge gains.

Authors:  Sheng Tong; Eli J Fine; Yanni Lin; Thomas J Cradick; Gang Bao
Journal:  Ann Biomed Eng       Date:  2013-12-03       Impact factor: 3.934

10.  Strep-tag II and Twin-Strep based cassettes for protein tagging by homologous recombination and characterization of endogenous macromolecular assemblies in Saccharomyces cerevisiae.

Authors:  Jay Rai; J Kalyani Pemmasani; Andriy Voronovsky; Ida S Jensen; Arulmani Manavalan; Jens R Nyengaard; Monika M Golas; Bjoern Sander
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.